https://www.selleckchem.com/pr....oducts/plerixafor-8h
e physiology of collagen. Current management of ulcerative colitis (UC) is aimed to treat active disease and to maintain remission. For patients in whom conventional treatment is no longer effective, biological or small molecule therapy may be an option. The aim was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of UC with infliximab (IFX), adalimumab (ADA), golimumab, vedolizumab (VDZ) and tofacitinib (TF compared with standard of care (SoC) in Poland. A hybrid decision tree/Marko
Like
Comment
Share
